Total failure day 28 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure [day 42 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐atovaquone‐proguanil (moderate certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artemether‐lumefantrine (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
Total failure day 28 PCR‐unadjusted · children under 5 years of age
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐unadjusted compared with artesunate‐amodiaquine (low certainty).
1 finding from 1 review
Total failure: day 42 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐adjusted compared with artesunate‐mefloquine (high certainty).
1 finding from 1 review
Total failure day 42 PCR‐unadjusted · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 42 PCR‐unadjusted compared with artesunate‐mefloquine (low certainty).
1 finding from 1 review
Total failure: day 28 (PCR‐adjusted) · children and adults
Atovaquone‐proguanil showed no clear difference in total failure day 28 PCR‐adjusted compared with artesunate‐atovaquone‐proguanil (low certainty).
1 finding from 1 review
Intervention not reported
Time taken to establish full gavage feeding (days) · intermittent bolus gavage tube feeding of preterm and low birth weight infants
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Feeding intolerance (number of episodes per day) · intermittent bolus gavage tube feeding of preterm and low birth weight infants
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Length of hospital stay · preterm infants
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ stoma formation (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ stoma… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ bowel resection (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ bowel… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).
1 finding from 1 review
Surgically‐related postoperative mortality (28 days to 6 months of surgery4) · women with advanced ovarian epithelial cancer
Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).
1 finding from 1 review
Adverse events (4 weeks' to 180 days' · primary Raynaud's phenomenon
1 finding from 1 review
Duration of attacks per day (minutes) · primary Raynaud's phenomenon
1 finding from 1 review
Migraine frequency Number of attacks · primary Raynaud's phenomenon
1 finding from 1 review